Where Is Sun Pharma Advanced Research Company Share Price Headed Over the Next 3 Years?

The Sun Pharma Advanced Research Company share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 259 on 10 July 2026, within a 52 week range of Rs 108 to Rs 289. This article lays out a scenario based Sun Pharma Advanced Research Company share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Research Company Company Overview

Sun Pharma Advanced Research Company is a research and development focused pharma company working on novel drug delivery platforms and new chemical entities, spun off from Sun Pharmaceutical Industries. Understanding the business model is the first step in framing any credible Sun Pharma Advanced Research Company share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company	Sun Pharma Advanced Research Company
NSE Ticker	SPARC
CMP (10 July 2026)	Rs 259
52 Week High	Rs 289
52 Week Low	Rs 108
Market Cap	Rs 8,412 Cr
Stock PE	5.39
Book Value	Rs 41.3
ROE	279%
ROCE	164%
Dividend Yield	0%

Where Does Sun Pharma Advanced Research Company Share Price Stand Today?

The stock currently trades about 10 percent below its 52 week high of Rs 289, which means the market has already tempered some of its optimism. For anyone building a Sun Pharma Advanced Research Company share price forecast, this correction matters for the Sun Pharma Advanced Research Company share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Sun Pharma Advanced Research Company commands a market capitalisation of Rs 8,412 Cr and trades at a price to earnings multiple of 5.39. The company generates a return on equity of 279% and a return on capital employed of 164%, which places it in the category of businesses with strong return ratios. These numbers anchor the Sun Pharma Advanced Research Company share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Sun Pharma Advanced Research Company Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Sun Pharma Advanced Research Company share price forecast between now and 2030, and together they explain most of the dispersion in this Sun Pharma Advanced Research Company share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With strong return ratios at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Sun Pharma Advanced Research Company share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Sun Pharma Advanced Research Company, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Sun Pharma Advanced Research Company against peers such as Sun Pharmaceutical Industries, Divis Laboratories and Laurus Labs on growth and valuations before forming a view on the Sun Pharma Advanced Research Company share price forecast.

Company Specific Catalysts

The bull case for Sun Pharma Advanced Research Company rests on progress on its novel drug pipeline and out-licensing deals for proprietary drug delivery technologies. If these play out on schedule, the Sun Pharma Advanced Research Company share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Sun Pharma Advanced Research Company share price forecast, while global risk aversion would do the opposite to the Sun Pharma Advanced Research Company share price outlook.

Sun Pharma Advanced Research Company Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Sun Pharma Advanced Research Company share price forecast using compounded annual growth assumptions applied to the current market price of Rs 259. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year	Bear Case	Base Case	Bull Case	Assumption
2027	Rs 280	Rs 305	Rs 330	5% to 18% CAGR on CMP
2028	Rs 295	Rs 345	Rs 390	5% to 18% CAGR on CMP
2030	Rs 325	Rs 430	Rs 545	5% to 18% CAGR on CMP

In the base case scenario of this Sun Pharma Advanced Research Company share price forecast, the 2030 level works out to roughly Rs 430, implying steady compounding from today’s levels. The bull case of Rs 545 assumes progress on its novel drug pipeline and out-licensing deals for proprietary drug delivery technologies delivers ahead of expectations, while the bear case of Rs 325 captures a scenario where growth stalls. That is an outcome band of about 25 percent to 110 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Sun Pharma Advanced Research Company Share Price

The Bull Case

The optimistic Sun Pharma Advanced Research Company share price forecast assumes progress on its novel drug pipeline and out-licensing deals for proprietary drug delivery technologies. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 545 by 2030.

The Bear Case

The cautious view centres on the fact that R&D stage companies carry binary trial outcome risk and have limited near term revenue to support valuations. If these pressures dominate, the Sun Pharma Advanced Research Company share price forecast would skew toward the lower band and the stock could stagnate near Rs 325 even by 2030, underperforming broader indices.

Key Risks That Could Change the Sun Pharma Advanced Research Company Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Sun Pharma Advanced Research Company share price forecast.
• Valuation risk: At a PE of 5.39, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: R&D stage companies carry binary trial outcome risk and have limited near term revenue to support valuations.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Sun Pharma Advanced Research Company Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Sun Pharma Advanced Research Company share price forecast lands in 2030 or what any single Sun Pharma Advanced Research Company share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around progress on its novel drug pipeline and out-licensing deals for proprietary drug delivery technologies gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Sun Pharma Advanced Research Company share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company share price live.

Conclusion

The Sun Pharma Advanced Research Company share price forecast for the next 3 years spans Rs 325 to Rs 545 by 2030 under the scenarios discussed, with a base case near Rs 430. Any credible Sun Pharma Advanced Research Company share price forecast must be updated as facts change, and the path will be decided by earnings delivery, progress on its novel drug pipeline and out-licensing deals for proprietary drug delivery technologies and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Sun Pharma Advanced Research Company share price forecast for the next 3 years?

Ans. The Sun Pharma Advanced Research Company share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 325 in the bear case to Rs 545 in the bull case, with a base case near Rs 430, depending on earnings delivery and market conditions.

What is the Sun Pharma Advanced Research Company share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 280 to Rs 330, with a base case around Rs 305. This assumes compounding on the current price of Rs 259 and is illustrative, not a guaranteed outcome.

What is the Sun Pharma Advanced Research Company share price forecast for 2028?

Ans. The 2028 scenario range is Rs 295 to Rs 390, with the base case near Rs 345. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Sun Pharma Advanced Research Company?

Ans. As of 10 July 2026, Sun Pharma Advanced Research Company trades at around Rs 259 on the NSE, within a 52 week range of Rs 108 to Rs 289. Prices change continuously during market hours, so check live quotes before acting.

Is Sun Pharma Advanced Research Company a good stock for the long term?

Ans. Sun Pharma Advanced Research Company has a credible long term story built on progress on its novel drug pipeline and out-licensing deals for proprietary drug delivery technologies, but it also carries risks since R&D stage companies carry binary trial outcome risk and have limited near term revenue to support valuations. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Sun Pharma Advanced Research Company share price outlook for 2030?

Ans. The Sun Pharma Advanced Research Company share price outlook for 2030 spans Rs 325 to Rs 545 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Sun Pharma Advanced Research Company share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of 5.39, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.